Please do not leave this page until complete. This can take a few moments.
Biohaven Pharmaceuticals Holding Company Ltd. announced this week it would pay Bristol-Myers Squibb $50 million as part of a deal to restructure its licensing agreement with the pharmaceutical giant for two cutting edge migraine drugs the New Haven firm is developing.
"This license agreement restructuring creates significant value for Biohaven and enhances our strategic flexibility moving forward,” Biohaven CEO Dr. Vlad Coric said.
The agreement will reduce Biohaven’s royalty payments to Bristol-Myers Squibb after the drugs are approved and marketed, Biohaven said. The reduction will be “in the mid-single digits,” setting the new royalties at “percentages in the low-to-mid teens,” the firm said.
Bristol-Myers Squibb also surrendered its right of first negotiation for intellectual property rights and to enter a license agreement with Biohaven on certain issues, Biohaven said.
Biohaven remains obligated to make development and milestone payments to Bristol-Myers Squibb in exchange for assistance in developing and marketing the drugs, the company said.
The two drugs covered by the agreement are the small molecule calcitonin gene-related peptide (CGRP) receptor antagonist platform, including its product candidates rimegepant, a potentially best-in-class CGRP receptor antagonist for the acute treatment of migraine, and BHV-3500, a third-generation antagonist to treat and prevent migraines.
The company raised $55 million to pay for the restructuring through the private sale of 2 million shares of common stock to institutional investors at $27.50 a share, according to the company.
Christopher Hoffman can be reached at news@newhavenbiz.com
This special edition informs and connects businesses with nonprofit organizations that are aligned with what they care about. Each nonprofit profile provides a crisp snapshot of the organization’s mission, goals, area of service, giving and volunteer opportunities and board leadership.
Learn moreHartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
SubscribeDelivering Vital Marketplace Content and Context to Senior Decision Makers Throughout Greater Hartford and the State ... All Year Long!
Read HereThis special edition informs and connects businesses with nonprofit organizations that are aligned with what they care about. Each nonprofit profile provides a crisp snapshot of the organization’s mission, goals, area of service, giving and volunteer opportunities and board leadership.
Hartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
Delivering Vital Marketplace Content and Context to Senior Decision Makers Throughout Greater Hartford and the State ... All Year Long!
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy
0 Comments